Keyphrases
Randomized Clinical Trial
100%
Intravitreous
100%
Proliferative Diabetic Retinopathy
100%
Panretinal Photocoagulation
100%
Ranibizumab
100%
Visual Acuity
40%
Diabetic Macular Edema
40%
Treatment Group
20%
Area under the Curve
20%
Group Differences
20%
Non-inferiority
20%
Vitrectomy
20%
Photocoagulation Treatment
20%
Retina
10%
Treatment Protocol
10%
January 2015
10%
Major Adverse Cardiovascular Events
10%
Neovascularization
10%
Treatment Completion
10%
Visual Field Defect
10%
Visual Loss
10%
Retinal Neovascularization
10%
Retreatment
10%
Between-group
10%
No Significant Difference
10%
Peripheral Visual Field
10%
Treatment Alternatives
10%
Intention-to-treat Analysis
10%
Endophthalmitis
10%
Visual Acuity Change
10%
Intravitreous Injection
10%
Visual Acuity Outcome
10%
Visual Field Sensitivity
10%
Noninferiority Margin
10%
Diabetic Retinopathy Treatment
10%
Peripheral Vision Loss
10%
Medicine and Dentistry
Randomized Clinical Trial
100%
Laser Coagulation
100%
Proliferative Diabetic Retinopathy
100%
Ranibizumab
100%
Visual Acuity
60%
Diabetic Macular Edema
40%
Visual Impairment
20%
Vitrectomy
20%
Visual Field
20%
Treatment Group
20%
Cardiovascular System
10%
Intention-to-Treat Analysis
10%
Retina Neovascularization
10%
Endophthalmitis
10%
Retreatment
10%
Peripheral Vision
10%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Clinical Trial
100%
Proliferative Diabetic Retinopathy
100%
Ranibizumab
100%
Diabetic Macular Edema
40%
Visual Impairment
20%
Treatment Group
20%
Retina Neovascularization
10%
Neovascularization (Pathology)
10%
Endophthalmitis
10%
Neuroscience
Ranibizumab
100%
Diabetic Retinopathy
100%
Endophthalmitis
10%